any drug

You medical provider will discuss many options with you and create a plan to help you meet your weight loss goals.

Retatrutide

INJECTABELE TRIPLE ACTION WEIGHT LOSS DRUG

RETATRUTIDE

Retatrutide is a new triple action drug for reducing over body fat and blood sugar. Retatrutide is known as a triple agonist of the glucose-dependent insulinotropic polypeptide (GIPR), glucagon-like peptide 1  (GLP-1) and glucagon receptors (GCCR) A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with Retatrutide 8 and 12 mg, respectively.

WHAT ARE THE BENEFITS RETATRUTIDE

• Regulates blood glucose and energy
• Stimulates glucagon release during hypoglycemia
• increases insulin secretion during hyperglycemia
• Promotes insulin secretion
• lowers blood glucose
• reduces body weight 
• reduces risk of cardiovascular disease
• reduces symptoms of angina

HOW DOES RETATRUTIDE WORK

Retatrutide has shown impressive benefit in obesity treatment through a triple action mechanism. It has triple agonist activity at:

• GLP-1R ( glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs),
• GIPR ( glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR)
• GCGR (glucagon (GCG) receptor (GCGR)
• Retatrutide, also known as LY3437943, is a peptide developed by Eli Lilly that activates these receptors. It’s a promising candidate for obesity research because it affects hunger regulation and blood sugar control. Retatrutide’s triagonist mode of action allows it to:
  • Release insulin from the pancreas in a glucose-dependent manner through GLP-1 receptors
  • Enhance the GLP-1-mediated effect through GIP receptors
  • Increase energy expenditure through glucagon receptors 
  In a phase 2 trial, retatrutide led to a 24.2% weight loss in people with obesity and without diabetes

 

HOW DOES RETATRUTIDE DIFFER FROM SEMAGLUTIDE AND TIRZEPATIDE

• Semaglutide (Wegovy) is the one of the the most successful treatments currently available acting on one of the three pivotal receptors regulating glucose homeostasison – glucagon-like peptide-1 (GLP-1) and termed a receptor agonists (GLP-1RAs), which was approved in 2017.  It mechanism of actionis on incretin hormone that stimulate postprandial insulin secretion
• Tirzepatide (Mounjaro) works by two methods to increase metabolic benefits; GLP-1R like semaglutide and it’s addition mode of action by activating glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) with the added benefit of reduced side-effects
• However, neither of these two medications Semaglutide nor Tirzepatidedo target glucagon (GCG) receptor (GCGR) like Retrutide does.

WHAT IS THE DOAGE OF RETATRUTIDE

• The medication is dosed once a week from 1 mg up to a maximum of 12 mg
• It  is commonly started at a low dose such as 1 mg or 2 mg and increased no more than every 4 weeks
• The average longterm dose was between 8 mg and 12 mg

HOW IS RETATRUTIDE SUPPLIED

• There are several options for medication available depending on the pharmacy.
• Here are some examples:
  • Retatrutide 2 mg per ml in a 2 ml vial
  • Retatrutide 2 mg per ml in a 4 ml vial
  • Retatrutide 8 mg per ml in a 2 ml vial
  • Retatrutide 8 mg per ml in a 4 ml vial

WHAT ARE THE SIDE EFFECTS OF RETATRUTIDE

There are very little side effects and those experienced are mild such as:

• nausea
• vomiting
• diarrhea
• constipation

What is important to note is many of the potential side effects were dose dependent. In other words, the higher the dose, the more likely one is to experience of or more side effects.

WANT TO LEARN MORE? SCHEDULE A CONSULTATION OR ASK A QUESTION BELOW